Regulatory Approval

Sequel Med Tech’s twiist system just gained FDA clearance for type 2 diabetes, signaling a massive shift in how millions will manage their insulin therapy.

As the U.S. races to rebuild its nuclear supply chain, LIS Technologies clears a critical regulatory hurdle, proving the business case for laser enrichment.

CMS approval for B. Braun's Stimuplex needles under the NOPAIN Act signals a major shift in how outpatient centers fund opioid-sparing pain management.

Centinel Spine just secured FDA two-level approval for its prodisc C Nova. Here is why tri-implant optionality is the end of one-size-fits-all spinal fusion.

Particula’s AAA rating for WisdomTree’s $1.2B tokenized fund signals a major shift in how Wall Street evaluates and trades blockchain-based assets.

Asian fintech YeePay has secured a crucial Dutch EMI license, signaling a major escalation in the global battle for Europe's B2B cross-border payment flows.

As iMDx prepares for the BTIG Kidney Health Forum, the diagnostics challenger is leveraging European clinical data to disrupt the post-transplant testing market.

The NMPA approval of a 6-month prostate cancer drug reveals how mid-tier biotechs navigate China's complex healthcare landscape via strategic partnerships.

Urolution Medical's FDA-cleared OpenFlo catheter challenges a century-old design, aiming to slash hospital infections without inflating supply chain costs.

With permits secured and $15 million in the bank, King Copper is deploying drills in southern Peru to chase a massive copper-gold porphyry system.

The AMA's Category I CPT code approval for Vektor Medical's vMap signals a major shift, turning computational ECGs into commercial reality.

Boehringer Ingelheim’s new quarterable PREVICOX tablets offer precise dosing for small dogs and slash supply chain waste, proving small tweaks yield big gains.

Oncodesign Precision Medicine is advancing its LRRK2 inhibitor OPM-201 toward Phase 1b. Here is how strategic repatriation and non-dilutive funding are paving the commercial pathway.

Bright Path Labs is using military-backed continuous-flow technology to reshore critical drug manufacturing, challenging the dominance of overseas APIs.

Last Energy’s DOE safety approval for its Texas microreactor highlights a pragmatic shift in nuclear strategy, targeting AI data centers with proven tech.

Stablecoin infrastructure provider Rain is abandoning the state-by-state regulatory patchwork, applying for a national trust bank charter to court institutions.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

AIRS Medical's FDA-cleared SwiftSight transforms MRI body composition into a sub-five-minute, radiation-free scan, unlocking new revenue for imaging centers.

Datasea’s FY2026 results reveal a bold strategy: slashing low-margin revenue by 43% to drive a 70% gross profit increase and fund a pivot to acoustic AI.